Compounds > diethylstilbestrol

diethylstilbestrol and docetaxel anhydrous

diethylstilbestrol has been researched along with docetaxel anhydrous in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujinami, K; Miura, T; Osada, Y; Takizawa, A1
Bossi, A; De La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C; Serrate, C1
Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S1

Other Studies

3 other study(ies) available for diethylstilbestrol and docetaxel anhydrous

ArticleYear
[Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2005, Volume: 51, Issue:1

    Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diethylstilbestrol; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids

2005
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Diethylstilbestrol; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome

2009
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
    British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome

2013